0P6S.L vs. NOVO-B.CO
Compare and contrast key facts about Bayer AG NA (0P6S.L) and Novo Nordisk A/S (NOVO-B.CO).
Performance
0P6S.L vs. NOVO-B.CO - Performance Comparison
Loading graphics...
0P6S.L vs. NOVO-B.CO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
0P6S.L Bayer AG NA | 7.46% | 92.83% | -42.42% | -28.37% | 7.41% | 1.36% | -30.83% | 26.05% | -39.06% | 8.46% |
NOVO-B.CO Novo Nordisk A/S | -24.70% | -46.44% | -9.91% | 50.83% | 29.14% | 76.14% | 13.26% | 32.53% | -8.71% | 35.09% |
Different Trading Currencies
0P6S.L is traded in EUR, while NOVO-B.CO is traded in DKK. To make them comparable, the NOVO-B.CO values have been converted to EUR using the latest available exchange rates.
Returns By Period
In the year-to-date period, 0P6S.L achieves a 7.46% return, which is significantly higher than NOVO-B.CO's -24.63% return. Over the past 10 years, 0P6S.L has underperformed NOVO-B.CO with an annualized return of -6.09%, while NOVO-B.CO has yielded a comparatively higher 5.25% annualized return.
0P6S.L
- 1D
- -0.42%
- 1M
- 3.76%
- YTD
- 7.46%
- 6M
- 36.61%
- 1Y
- 86.57%
- 3Y*
- -10.95%
- 5Y*
- -3.46%
- 10Y*
- -6.09%
NOVO-B.CO
- 1D
- 2.73%
- 1M
- 5.97%
- YTD
- -24.63%
- 6M
- -33.93%
- 1Y
- -46.96%
- 3Y*
- -22.22%
- 5Y*
- 4.03%
- 10Y*
- 5.25%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
0P6S.L vs. NOVO-B.CO — Risk / Return Rank
0P6S.L
NOVO-B.CO
0P6S.L vs. NOVO-B.CO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Bayer AG NA (0P6S.L) and Novo Nordisk A/S (NOVO-B.CO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| 0P6S.L | NOVO-B.CO | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.22 | -0.88 | +3.10 |
Sortino ratioReturn per unit of downside risk | 2.93 | -1.12 | +4.05 |
Omega ratioGain probability vs. loss probability | 1.39 | 0.85 | +0.54 |
Calmar ratioReturn relative to maximum drawdown | 3.70 | -0.87 | +4.57 |
Martin ratioReturn relative to average drawdown | 11.58 | -1.48 | +13.06 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| 0P6S.L | NOVO-B.CO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.22 | -0.88 | +3.10 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.11 | 0.11 | -0.22 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.16 | 0.16 | -0.32 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.08 | 0.47 | -0.40 |
Correlation
The correlation between 0P6S.L and NOVO-B.CO is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
0P6S.L vs. NOVO-B.CO - Dividend Comparison
0P6S.L's dividend yield for the trailing twelve months is around 0.28%, less than NOVO-B.CO's 4.94% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
0P6S.L Bayer AG NA | 0.28% | 0.30% | 0.57% | 7.14% | 4.09% | 4.25% | 5.81% | 3.84% | 4.62% | 2.64% | 2.59% | 1.97% |
NOVO-B.CO Novo Nordisk A/S | 4.94% | 3.58% | 1.59% | 1.01% | 1.19% | 1.27% | 2.02% | 2.11% | 2.64% | 2.27% | 3.69% | 1.25% |
Drawdowns
0P6S.L vs. NOVO-B.CO - Drawdown Comparison
The maximum 0P6S.L drawdown since its inception was -82.30%, which is greater than NOVO-B.CO's maximum drawdown of -76.81%. Use the drawdown chart below to compare losses from any high point for 0P6S.L and NOVO-B.CO.
Loading graphics...
Drawdown Indicators
| 0P6S.L | NOVO-B.CO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -82.30% | -76.75% | -5.55% |
Max Drawdown (1Y)Largest decline over 1 year | -23.03% | -54.94% | +31.91% |
Max Drawdown (5Y)Largest decline over 5 years | -70.73% | -76.75% | +6.02% |
Max Drawdown (10Y)Largest decline over 10 years | -80.48% | -76.75% | -3.73% |
Current DrawdownCurrent decline from peak | -62.34% | -75.38% | +13.04% |
Average DrawdownAverage peak-to-trough decline | -33.78% | -15.80% | -17.98% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.37% | 32.14% | -24.77% |
Volatility
0P6S.L vs. NOVO-B.CO - Volatility Comparison
Bayer AG NA (0P6S.L) has a higher volatility of 10.41% compared to Novo Nordisk A/S (NOVO-B.CO) at 9.13%. This indicates that 0P6S.L's price experiences larger fluctuations and is considered to be riskier than NOVO-B.CO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| 0P6S.L | NOVO-B.CO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.41% | 9.13% | +1.28% |
Volatility (6M)Calculated over the trailing 6-month period | 28.35% | 40.82% | -12.47% |
Volatility (1Y)Calculated over the trailing 1-year period | 39.09% | 55.46% | -16.37% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 31.06% | 38.38% | -7.32% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 39.13% | 32.54% | +6.59% |
Financials
0P6S.L vs. NOVO-B.CO - Financials Comparison
This section allows you to compare key financial metrics between Bayer AG NA and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities